Dilara Irem Arslan Kahraman

Dilara Irem Arslan Kahraman

Auto-generated profile, based on publicly available information

Dilara Irem Arslan Kahraman

Department of Pathology Ankara Etlik City Hospital Ankara Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
HOHayrunnisa Oral
Hayrunnisa Oral
ZTZafer Turkyilmaz
Zafer Turkyilmaz
DKDilara İrEm Arslan Kahraman
Dilara İrEm Arslan Kahraman
CKCEM KAYA
CEM KAYA
RKRamazan Karabulut
Ramazan Karabulut
KSKaan Sönmez
Kaan Sönmez
Click on the article title to read more.

13 June 2024 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
DADilara Irem Arslan-Kahraman
Dilara Irem Arslan-Kahraman
BOBetul Ogut
Betul Ogut
MIMehmet Arda Inan
Mehmet Arda Inan
FKFerah Kazanci
Ferah Kazanci
MOMehmet Anil Onan
Mehmet Anil Onan
OEOzlem Erdem
Ozlem Erdem
The aim of this study is to evaluate the expressions of programmed death-ligand 1 (PD-L1), V-domain Ig suppressor of T-cell activation (VISTA), lymphocyte activation gene-3 (LAG-3), and galectin-3 (GAL-3), in mismatch repair-deficient (MMRd)/MMR-proficient and abnormal p53 expressing endometrial carcinomas and their relationship with clinical-histopathological features. Patients who underwent surgery for endometrial carcinoma between January 2008 and December 2018 were included in the study. Immunohistochemical analysis of MLH1, PMS2, MSH2, MSH6, p53, PD-L1, VISTA, LAG-3, and GAL-3 was performed on the tissue samples of microarray. A total of 529 patients were included. MMRd and p53-mutant tumors accounted for 31.5% and 11.5% of cases, respectively. PD-L1 and LAG-3 expressions in the MMRd and p53-mutant groups were higher than in the MMR-proficient group (P < 0.001). GAL-3 expression in the MMR-proficient group was statistically higher than in the MMRd and p53-mutant groups (P < 0.001). Mean age, grade, International Federation of Gynecology and Obstetrics stage, lymphovascular invasion, and lymph node metastasis were significantly higher in the p53-mutant group (P < 0.001). In the group with PD-L1 expression, nonendometrioid histologic type, tumor grade, and lymphovascular invasion were significantly higher (P < 0.001). Tumor grade, lymphovascular invasion, lymph node metastasis, and microcystic, elongated and fragmented pattern of invasion were significantly higher in the group with high VISTA expression (P < 0.05). Tumor grade was significantly higher in the group with LAG-3 expression (P < 0.001). Immunohistochemically determined subgroups and PD-L1, VISTA, LAG-3, and GAL-3 expression levels may be useful indicators of molecular features, and clinical outcomes also may have important implications for the development of targeted therapies in endometrial carcinoma.

5 May 2026 in Histopathology
Verified
Journal Article
Open access
PDF file
BBBusra Yaprak Bayrak
Busra Yaprak Bayrak
KKKemal Kosemehmetoglu
Kemal Kosemehmetoglu
BOBusra Ozbek
Busra Ozbek
SSSercan Simsek
Sercan Simsek
MOMurat Oktay
Murat Oktay
MAMahmut Akgul
Mahmut Akgul
Aims: Plasmacytoid urothelial carcinoma (PUC) is an aggressive morphological subtype characterized by discohesive single‐cell infiltration and frequent loss of epithelial adhesion. Although p63 is widely regarded as a reliable urothelial lineage marker in conventional urothelial carcinoma, its expression may be reduced or absent in plasmacytoid tumours, creating an important diagnostic pitfall. This multi‐institutional study aimed to characterize the clinicopathological and immunohistochemical profile of PUC, with particular emphasis on p63 immunoreactivity and its relationship to adhesion‐related markers and other diagnostically relevant immunophenotypes. Methods and results: A total of 93 cases initially diagnosed as PUC were retrospectively reviewed across multiple centres. After histopathological re‐evaluation, 70 confirmed cases were included. Immunohistochemical analysis was performed for p63, e‐cadherin, p120 catenin, TRPS1, HER2/Neu . The cohort comprised 70 patients with a median age of 66.5 years (IQR, 59.8–72.0) and a strong male predominance of 85.7% (60/70). Most specimens were obtained from transurethral resections (64.3%, 45/70) and radical cystectomy specimens (34.3%, 24/70). The median tumour size was 3.0 cm (IQR, 1.0–5.0), and the median proportion of plasmacytoid differentiation was 80% (IQR, 20–100). Morphologically, tumours were classified as classic plasmacytoid in 65.7% (46/70), pleomorphic in 22.9% (16/70) and desmoplastic in 11.4% (8/70). Concurrent variant histology was identified in 21.4% (15/70), most commonly micropapillary (12.9%, 9/70) and sarcomatoid (7.1%, 5/70) components. Lymphovascular invasion was present in 51.4% (36/70), and concomitant carcinoma in situ was detected in 35.7% (25/70). Immunohistochemically, p63 expression was retained in only 10.0% of tumours (7/70). HER2 membranous overexpression was observed in 58.6% (41/70), while loss of E‐cadherin expression was highly prevalent (84.3%, 59/70). Aberrant p120 catenin expression was common, with cytoplasmic localization in 72.9% (51/70) and complete loss in 17.1% (12/70). TRPS1 immunostaining was available in 54 tumours and was negative in 92.6% of evaluable cases (50/54). Conclusion: PUC demonstrates a distinctive immunophenotype characterized by frequent loss of p63 and disruption of the e‐cadherin/p120 adhesion complex. Recognition of p63 attenuation, together with adhesion‐related markers and HER2 status, provides a useful diagnostic framework for distinguishing this aggressive subtype from conventional urothelial carcinoma and its mimickers.

14 November 2026 in Virchows Archiv
Verified
Journal Article
Closed access
BBBusra Yaprak Bayrak
Busra Yaprak Bayrak
MOMurat Oktay
Murat Oktay
MBMelek Buyukgok
Melek Buyukgok
FSFadime Eda Gökalp Satıcı
Fadime Eda Gökalp Satıcı
MKMerve meryem Kıran
Merve meryem Kıran
MAMahmut Akgul
Mahmut Akgul

16 March 2021
Verified
Book Chapter
Closed access
PDF file
FDFatma Hüsniye Dilek
Fatma Hüsniye Dilek
DKDilara İrEm Arslan Kahraman
Dilara İrEm Arslan Kahraman

13 April 2026 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
NYNazif Alperen Yildirim
Nazif Alperen Yildirim
YKYasemin Yuyucu Karabulut
Yasemin Yuyucu Karabulut
DTDuygu Turkbey
Duygu Turkbey
EOEce Ozturk
Ece Ozturk
DKDilara Irem Arslan Kahraman
Dilara Irem Arslan Kahraman
MAMahmut Akgul
Mahmut Akgul